Teva Pharmaceutical Industries Limited

NYSE:TEVA Rapport sur les actions

Capitalisation boursière : US$21.0b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Teva Pharmaceutical Industries Croissance future

Future contrôle des critères 4/6

Teva Pharmaceutical Industries devrait augmenter ses bénéfices et son chiffre d'affaires de 50.7% et de 2.5% par an respectivement. Le BPA devrait croître de de 42.7% par an. Le rendement des capitaux propres devrait être 29.2% dans 3 ans.

Informations clés

50.7%

Taux de croissance des bénéfices

42.7%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices23.6%
Taux de croissance des recettes2.5%
Rendement futur des capitaux propres29.2%
Couverture par les analystes

Good

Dernière mise à jour22 Aug 2024

Mises à jour récentes de la croissance future

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Teva's Transformation: From Generics Leader To Branded Drug Innovator

Aug 14

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs

Jul 26

Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Jul 12
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Teva Pharmaceutical: Buy This Bargain Before It's Gone

Jun 07

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 14
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)

May 09

Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

Mar 26
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

Teva Pharmaceutical Industries: Potential Outweighs Concerns

Mar 25

Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities

Feb 26

A Review Of Teva's Prospects

Feb 15

Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry

Jan 07
Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry

These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way

Dec 11
These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way

Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)

Dec 08

Teva: Deeply Undervalued FCF Machine

Nov 20

Teva: Focus On Innovation And Growth Means The Times They Are A Changing

Sep 14

Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt

Sep 09
Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider

Aug 26

Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain

Aug 02

Teva Pharmaceutical: Lacking Capabilities For Strategic Investments

Jul 20

Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence

Jun 15

Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load

Jun 06
Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load

Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Feb 20
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

What To Expect From Teva Pharmaceutical In 2023 With A New CEO

Feb 15

Can Teva Pharmaceutical's Q4 results bring positive surprise?

Feb 07

Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment

Jan 19

Tamiflu supplies released from national stockpile as nationwide shortage persists

Jan 12

Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year

Dec 28

Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex

Dec 16

Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit

Nov 10

Teva Pharmaceutical to pay New York $523M as part of opioid settlement

Nov 03

Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's

Oct 18

Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg

Oct 06

Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price

Sep 28

Teva Pharmaceutical: Past Behind And A Promising 2023

Sep 16

Prévisions de croissance des bénéfices et des revenus

NYSE:TEVA - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202617,3331,7403,4122,1618
12/31/202516,8141,5032,8402,2809
12/31/202416,213-4892,4572998
6/30/202416,290-4536791,168N/A
3/31/202416,004-4788781,389N/A
12/31/202315,846-5598421,368N/A
9/30/202315,273-2,3256081,157N/A
6/30/202315,017-2,3501,1731,695N/A
3/31/202314,925-1,7119641,494N/A
12/31/202214,925-2,4461,0421,590N/A
9/30/202215,141-1,2915141,073N/A
6/30/202215,433-1,0544761,059N/A
3/31/202215,557-6155851,154N/A
12/31/202115,878417236798N/A
9/30/202116,23172688673N/A
6/30/202116,324-3,915-131451N/A
3/31/202116,284-3,982-94506N/A
12/31/202016,659-3,9906381,216N/A
9/30/202016,673-4,0319021,423N/A
6/30/202016,78848941,441N/A
3/31/202017,095-825413941N/A
12/31/201916,887-999223748N/A
9/30/201916,396-4,048-42577N/A
6/30/201916,831-4,00784673N/A
3/31/201917,355-3,5594491,062N/A
12/31/201818,271-2,3991,7952,446N/A
9/30/201819,693-11,0592,2332,938N/A
6/30/201820,781-10,2562,5343,312N/A
3/31/201821,800-16,050N/A3,585N/A
12/31/201721,853-16,525N/A2,225N/A
9/30/201723,479-5,963N/A2,791N/A
6/30/201723,425-6,145N/A3,457N/A
3/31/201722,74378N/A3,985N/A
12/31/201621,90368N/A3,890N/A
9/30/201620,2921,591N/A5,415N/A
6/30/201619,5521,346N/A5,047N/A
3/31/201619,4801,697N/A5,564N/A
12/31/201519,6521,573N/A5,542N/A
9/30/201519,9391,775N/A5,679N/A
6/30/201520,1742,548N/A6,010N/A
3/31/201520,2532,757N/A5,583N/A
12/31/201420,2723,055N/A5,127N/A
9/30/201420,5342,748N/A4,191N/A
6/30/201420,5352,583N/A3,211N/A
3/31/201420,4141,383N/A3,033N/A
12/31/201320,3141,269N/A3,237N/A
9/30/201320,1331,209N/A3,998N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: TEVA devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.5% ).

Bénéfices vs marché: TEVA devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: TEVA devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de TEVA ( 2.5% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de TEVA ( 2.5% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de TEVA devrait être élevé dans 3 ans ( 29.2 %)

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y